Credence

Pfizer Licenses Starna's In Vivo CAR-T Technology in $2.63B Autoimmune Disease Deal


Key Points

  • Pfizer signed an exclusive licensing deal with Starna Therapeutics for three preclinical in vivo CAR-T programs targeting autoimmune diseases, with rights outside Greater China.
  • The deal includes $330 million upfront and up to $2.3 billion in milestones plus royalties, plus access to Starna's RNA and targeted LNP platform.
  • In vivo CAR-T generates CAR-expressing cells inside the body, aiming to reset dysfunctional immune responses as an alternative to conventional ex vivo CAR-T.

Pfizer has signed an exclusive licensing agreement with biotechnology company Starna Therapeutics to advance three preclinical in vivo chimeric antigen receptor T-cell (CAR-T) programs targeting autoimmune diseases, expanding the pharmaceutical company’s inflammation and immunology pipeline. Under the agreement, Pfizer will secure exclusive rights outside Greater China to develop, manufacture and commercialize the three programs. The deal also provides Pfizer with access to Starna’s proprietary in vivo CAR-T technology for applications in inflammation and immunology, as well as oncology.

The agreement includes additional options allowing Pfizer to exclusively license compounds generated through a separate research collaboration and potentially expand its territorial rights into Greater China. The financial terms include a $330 million upfront payment to Starna, which is also eligible for up to $2.3 billion in development and commercial milestone payments, along with royalties on net sales of any resulting approved products.

The collaboration brings together Starna’s RNA-based therapeutic technologies and Pfizer’s experience in RNA medicine development, manufacturing and immunology research. In vivo CAR-T approaches are designed to generate CAR-expressing immune cells directly inside the patient’s body, potentially offering an alternative to conventional ex vivo CAR-T treatments, which require collecting a patient’s T cells, genetically modifying them outside the body and reinfusing them. The technology is attracting interest beyond oncology, particularly in autoimmune diseases, where researchers are investigating whether engineered T cells could help eliminate disease-associated immune cells and potentially reset dysfunctional immune responses.

Starna’s platform combines RNA technology with targeted lipid nanoparticle (LNP) delivery to support the development of in vivo therapeutic approaches. The company believes this delivery system could provide a foundation for advancing CAR-T candidates across autoimmune and cancer indications.

“In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short,” says Michael Vincent, MD, PhD, chief inflammation and immunology officer at Pfizer. He added that Starna’s technology provides an opportunity to apply Pfizer’s RNA development and manufacturing capabilities to a next-generation cell therapy approach.

Rongkuan Hu, PhD, CEO of Starna Therapeutics, says the collaboration will combine the company’s targeted LNP delivery and RNA technologies with Pfizer’s global drug development capabilities to advance potential treatments.

Pfizer will assume responsibility for clinical development outside Greater China and plans to manufacture finished drug product for the initial clinical trials at its U.S. facilities. The pharmaceutical company will also retain exclusive control over commercialization of licensed products in territories covered by the agreement.

For Starna, the transaction provides substantial upfront funding and the opportunity to participate in the long-term commercial value of its technology through milestone payments and royalties. The reciprocal licensing and research options also create opportunities to expand the collaboration into additional therapeutic programs.

The agreement represents another investment in the emerging application of engineered cell therapies for diseases beyond cancer. While CAR-T therapies have primarily advanced through oncology programs, growing research interest in autoimmune diseases has created opportunities to investigate whether targeted immune-cell modification could provide longer-lasting disease control.

By combining Starna’s in vivo delivery platform with Pfizer’s capabilities in RNA medicines, immunology research, clinical development and global manufacturing, the companies aim to advance a new generation of potential treatments for patients with autoimmune disorders. The three licensed programs remain at the preclinical, pre-investigational new drug (pre-IND) stage, meaning substantial research, clinical development and regulatory work will be required before any potential therapies could reach the market.

Visit www.pfizer.com for more information.